Oppenheimer Asset Management Inc. Has $2.41 Million Holdings in Avantor, Inc. (NYSE:AVTR)

Oppenheimer Asset Management Inc. trimmed its position in Avantor, Inc. (NYSE:AVTR) by 2.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 93,139 shares of the company’s stock after selling 2,691 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Avantor were worth $2,410,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. 1832 Asset Management L.P. boosted its holdings in Avantor by 1,634.9% during the second quarter. 1832 Asset Management L.P. now owns 8,530,118 shares of the company’s stock valued at $180,839,000 after purchasing an additional 8,038,451 shares in the last quarter. Sound Shore Management Inc. CT bought a new position in shares of Avantor during the 2nd quarter worth approximately $76,412,000. Principal Financial Group Inc. boosted its stake in Avantor by 146.5% in the 3rd quarter. Principal Financial Group Inc. now owns 2,628,372 shares of the company’s stock valued at $67,996,000 after buying an additional 1,562,018 shares in the last quarter. Canada Pension Plan Investment Board grew its position in Avantor by 6.8% in the second quarter. Canada Pension Plan Investment Board now owns 22,927,325 shares of the company’s stock valued at $486,059,000 after acquiring an additional 1,463,695 shares during the period. Finally, Magnetar Financial LLC acquired a new position in Avantor during the first quarter worth $35,154,000. 95.08% of the stock is owned by institutional investors.

Insider Transactions at Avantor

In other news, CAO Steven W. Eck sold 3,525 shares of the firm’s stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total value of $88,336.50. Following the transaction, the chief accounting officer now directly owns 29,544 shares in the company, valued at $740,372.64. This trade represents a 10.66 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.50% of the stock is owned by corporate insiders.

Avantor Stock Performance

Shares of NYSE:AVTR opened at $20.74 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84. Avantor, Inc. has a 1-year low of $19.11 and a 1-year high of $28.00. The stock has a market capitalization of $14.12 billion, a P/E ratio of 45.09, a P/E/G ratio of 2.61 and a beta of 1.35. The business has a 50-day moving average price of $24.52 and a two-hundred day moving average price of $24.01.

Analyst Ratings Changes

AVTR has been the topic of several recent analyst reports. UBS Group reduced their target price on shares of Avantor from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Tuesday, October 8th. Wells Fargo & Company reduced their price target on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, October 28th. Robert W. Baird dropped their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 28th. Royal Bank of Canada reiterated an “outperform” rating and issued a $34.00 target price on shares of Avantor in a research note on Thursday, September 26th. Finally, Stifel Nicolaus increased their price target on Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a research report on Monday, July 29th. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, Avantor has a consensus rating of “Moderate Buy” and an average price target of $27.57.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.